A Case of Complete Regression of Hepatocellular Carcinoma during Administration of COX-2 Inhibitor.
- Author:
Hae Jung SONG
1
;
Yun Soo KIM
;
Chang Hee HAN
;
Jae Young JANG
;
Jung Hoon KIM
;
Young Koog CHEON
;
Young Seok KIM
;
Jong Ho MOON
;
Young Deok CHO
;
Chan Sup SHIM
;
Kui Hyang KWON
;
Boo Sung KIM
Author Information
1. Institute for Digestive Research, Department of Internal Medicine, Soon Chun Hyang University, College of Medicine, Seoul, Korea.
- Publication Type:Case Report ; English Abstract
- Keywords:
Hepatocellular carcinoma;
Complete regression;
COX-2 inhibitor;
Celecoxib
- MeSH:
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Carcinoma, Hepatocellular/*drug therapy;
Cyclooxygenase 2 Inhibitors/administration & dosage/*therapeutic use;
Diclofenac/administration & dosage/analogs & derivatives/therapeutic use;
Female;
Humans;
Lactones/administration & dosage/therapeutic use;
Liver Neoplasms/*drug therapy;
Pyrazoles/administration & dosage/therapeutic use;
Sulfonamides/administration & dosage/therapeutic use;
Sulfones/administration & dosage/therapeutic use
- From:The Korean Journal of Hepatology
2006;12(3):449-454
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Overexpression of cyclooxygenase-2 (COX-2) has been associated with hepatocarcinogenesis. Inhibitors of COX-2 have proapoptotic and antiproliferative effects on malignant tumors and inhibit tumor invasion to the surrounding tissues. We report here a case of complete regression of advanced hepatocellular carcinoma (HCC) during COX-2 inhibitor administration. An eighty-year-old female was diagnosed as an advanced HCC, which was associated with HCV infection. She received COX-2 inhibitor for 3 months due to degenerative arthritis of both knees. Tumor enhancement on arterial phase CT completely disappeared without specific treatment for the HCC, and the tumor size decreased on the follow-up CT scan.
